Keeping checkpoint kinases in line: New selective inhibitors in clinical trials

Keyphrases

• Clinical Trials 100%
• Selective Inhibitor 100%
• Checkpoint Kinase 1 (CHK1) 100%
• DNA Damage Response 50%
• Cancer Therapy 25%
• Tumor 25%
• DNA Damage 25%
• Kinase Function 25%
• Cell Cycle Progression 25%
• Phase I Clinical Trial 25%
• Tumor-specific 25%
• Therapeutic Utility 25%
• Serine-threonine Kinase 25%
• Response Pathways 25%
• AZD7762 25%
• DNA Damage Recognition 25%

Medicine and Dentistry

• Clinical Trial 100%
• Kinase 100%
• Checkpoint Kinase 1 66%
• Cancer Therapy 33%
• DNA Damage 33%
• Tumor 33%
• Phosphotransferase 33%
• Specific Tumor 33%
• Cell Cycle Progression 33%
• DNA Damage Response 33%
• Protein Serine Threonine Kinase 33%
• 5 (3 Fluorophenyl) N (3 Piperidinyl) 3 Ureido 2 Thiophenecarboxamide 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Checkpoint Kinase 1 100%
• Phosphotransferase 50%
• Malignant Neoplasm 50%
• Protein Serine Threonine Kinase 50%
• 5 (3 Fluorophenyl) N (3 Piperidinyl) 3 Ureido 2 Thiophenecarboxamide 50%